InflaRx (IFRX) Stock Forecast & Price Target

InflaRx is viewed positively because izicopan offers a differentiated oral C5aR profile in ANCA-associated vasculitis, where Tavneos validated the mechanism but is now burdened by hepatotoxicity, dosing inconvenience, and regulatory scrutiny. Its clinical and pharmacokinetic package is compelling, with >180 subjects dosed, no SAEs or TEAEs to date, roughly 3-fold higher Cmax, 10-fold higher AUC, and rapid target saturation within days, while physician survey data showed 69% would switch and 92% would prescribe more of a safer class option. The company also has meaningful balance-sheet support, ending 1Q26 with €39.8M in cash and marketable securities excluding the recent offering of about €127M, which is expected to fund runway through 2029.

InflaRx is viewed negatively because its lead opportunity in C5aR inhibition sits behind a class marred by hepatotoxicity concerns, slow onset, and incomplete durability, while survey data show physicians want a safer, faster-acting oral alternative but are already skeptical of the incumbent standard. The company also faces weak current economics and commercialization limitations, with approximately €18.0M of SG&A expense in 2025 against about €29K revenue and a stated need for additional funding before profitability, suggesting ongoing dilution risk and limited near-term operating leverage. In addition, regulatory and competitive pressure on the broader AAV market, including the possibility that Tavneos could be removed and the existence of approved, established therapies, makes it difficult for InflaRx’s candidates to win share without clear differentiation.